Life, illuminated.
Advancing fluorescent technology to help improve patient care.

MediBeacon is a medical technology company specializing in the advances of fluorescent tracer agents and transdermal measurement. The science is complex, but the outcomes are simple to understand. How it works >>

PRECLINICAL
MediBeacon technology is available for preclinical use.
CLINICAL
MediBeacon technologies are progressing through clinical trials.*
There are no limits to our thinking or what that thinking can accomplish.
Focus areas for
fluorescent agent-
based systems include:
Nephrology

Point of care measurement of renal function **
-Learn More

Gastroenterology

Point of care gastrointestinal
permeability measurement
-Learn More

Ophthalmology

Fluorescent agent angiography
-Learn More

Surgery

Fluorescent tracer agent
use in surgery
-Learn More

Acute Kidney Injury complicates as many as
36%of cardiac operations worldwide
  • Doubling total hospital costs
  • AKI predicts increased long-term mortality
  • Clinicians have limited tools to identify patients at risk of AKI
  • Identification of high-risk patients preoperatively could affect clinical decision making
- The Society of Thoracic Surgeons, Mitchell Rosner, John Kellum, and Claudio Ronco et al., Preoperative renal functional reserve predicts risk of Acute Kidney Injury (AKI) after cardiac operation, 2018

MediBeacon’s Transdermal Glomerular Filtration Rate Measurement System (TGFR) has the potential to provide important information to cardiologists to address this challenge.
THE UNMET MEDICAL NEED IN THE INTENSIVE CARE UNIT:
Acute Kidney Injury occurred in more than
50%
of ICU patients.
- Intensive Care Medicine, Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study, 2015
MediBeacon’s Transdermal Glomerular Filtration Rate Measurement System (TGFR) has the potential to provide important information to Intensive Care Unit professionals to address this challenge.